PAH WHO Group I
Also known as: Pulmonary arterial hypertension WHO functional class I / Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) / WHO Group 1 Pulmonary arterial hypertension / Pulmonary Arterial Hypertension WHO Group I / Pulmonary Arterial Hypertension / Pulmonary hypertensive arterial disease (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB06403 | Ambrisentan | A selective type A endothelin receptor antagonist used to treat primary pulmonary arterial hypertension and pulmonary arterial hypertension based on diagnostic classifications. |
| DB08932 | Macitentan | An endothelin receptor antagonist used to manage pulmonary arterial hypertension to delay disease progression. |
| DB11362 | Selexipag | A non prostanoid IP prostacyclin receptor agonist used to treat pulmonary arterial hypertension. |
| DB12118 | Sotatercept | A recombinant activin receptor fusion protein used to treat pulmonary arterial hypertension. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB08932 | Macitentan | 3 | Active Not Recruiting | 1 |
| DB00820 | Tadalafil | 3 | Active Not Recruiting | 1 |
| DB06403 | Ambrisentan | Not Available | Withdrawn | 1 |
| DB00559 | Bosentan | Not Available | Withdrawn | 1 |
| DB06268 | Sitaxentan | Not Available | Withdrawn | 1 |